U.S. Clinical Trial Supply and Logistics Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 1.54 Bn

Forecast Year, 2035

USD 3.13 Bn

CAGR, 2026 - 2035

7.35%

Report Coverage

U.S.

U.S. Clinical Trial Supply and Logistics Market Size and Forecast 2026 to 2035

The U.S. clinical trial supply and logistics market size accounted for USD 1.54 billion in 2025 and is predicted to increase from USD 1.66 billion in 2026 to approximately USD 3.13 billion by 2035, expanding at a CAGR of 7.35% from 2026 to 2035. The market is driven by the rising number of complex clinical trials, increasing demand for biologics and personalized medicine, and growing need for temperature-controlled and time-sensitive drug distribution across decentralized trial sites.

Key Takeaways

• By service, the logistics & distribution segment held the largest share of the market in 2025.
• By service, the manufacturing segment is expected to grow at the fastest CAGR during the forecast period.
• By phase, the phase III segment dominated the market in 2025.
• By phase, the phase II segment is expected to grow at the fastest CAGR between 2026 and 2035.
• By therapeutic area, the cardiovascular diseases segment led the market in 2025.
• By therapeutic area, the oncology segment is expected to grow with a significant CAGR during the forecast period.
• By end user, the pharmaceuticals segment held the largest share of the market in 2025.
• By end-user, the biologicals segment is expected to grow with the highest CAGR during the forecast period.

Market Overview

The U.S. clinical trial supply chain and logistics industry is growing significantly due to the widespread adoption of precision medicines for the treatment of rare diseases. The biopharma companies are collaborating with 3PL providers to transport medicinal items in isolated areas. In addition, the rapid investments made by the government for strengthening the logistics sector have significantly contributed to the industry.

What is the Role of AI in the U.S. Clinical Trial Supply and Logistics Market?

AI is playing a transformative role in the development of the U.S. clinical trial supply and logistics industry. AI helps to shift the supply chain from a manual process to a highly automated one. It is also used to reduce drug wastage, eliminate hidden bottlenecks, and prevent patient-dosing risks. Machine learning algorithms are continuously used to monitor the expiry dates of investigational products and adjust distribution paths to ensure the quality of the products and minimize costs.

• In June 2026, Medidata launched an AI-powered imaging solution. This imaging solution is designed to enhance clinical trial analysis of advanced therapies.

Market Report Coverage and Key Metrics

Market Dynamics

Drivers

Increasing Demand for Precision Therapies

The demand for precision therapies has been increasing rapidly due to the growing incidence of cancer, along with a large pool of the aging population. Also, the availability of improved diagnostic capabilities and the rapid shift toward life-prolonging personalized medicines are driving the market. The rising cases of rare genetic disorders further increase the adoption of precision drugs. With the growing demand for precision therapies, clinical trial activities are rising significantly to validate the efficacy of these therapies.

In February 2026, the Advanced Research Projects Agency for Health announced the opening of the first of three adaptive oncology clinical trials under its Advanced Analysis for Precision Cancer Therapy Program. This program deals in providing an adaptive approach for monitoring and treating cancers by integrating detailed biological data of patients with real-time analytical insights.

Restraint

Supply Chain Vulnerabilities and Growing Prices of Cold-Chain Logistics Services

Pharma companies are facing numerous problems in conducting clinical trials due to a lack of a well-organized supply chain. The cost of cold-chain logistics services has been growing significantly owing to the increasing prices of diesel, which in turn restrains the market growth.

Opportunity

Cryogenic Logistics and Digital Transformation in Clinical Trial Methodology

Rising demand for cryogenic logistics creates immense opportunities in the U.S. clinical trial supply and logistics market. Cryogenic logistics delivers ultra-low temperature control below 150 °C to store and transport highly sensitive biological and pharmaceutical products. The healthcare organizations are rapidly integrating AI platforms and sensor technology to enhance clinical trial processes. Thus, the integration of advanced technologies in the healthcare sector, as well as the surging popularity of cryogenic logistics, is anticipated to create opportunities in the future.

How is the Government Helping the U.S. Clinical Trial Supply and Logistics Market?

The U.S. government has been supporting the clinical trial supply and logistics industry through federal funding. It has also facilitated regulatory modernization and launched infrastructure-related initiatives to ensure supply chain resilience, protect trial integrity, and expand patient access across the U.S. The National Institutes of Health (NIH) is the fundamental governmental body which deals in conducting clinical trials across the U.S.

Market Segmentation Analysis

Service Insights

What Made Logistics & Distribution the Leading Segment in the Market?

The logistics & distribution segment held the largest share of the U.S. clinical trial supply and logistics market in 2025. This is mainly due to the rising investment by the government in strengthening the road infrastructure to enhance logistics operations. The logistics operators have started delivering medicinal items on new routes to enhance their brand presence. Moreover, the pharma brands are partnering with regional distributors to enhance their supply-chain operations.

The manufacturing segment is expected to grow at the fastest CAGR in the coming years due to the rising demand for specialized production of clinical trial materials, particularly for biologics, cell and gene therapies, and personalized medicines. Increasing outsourcing of manufacturing activities to ensure scalability, regulatory compliance, and cost efficiency is further driving segment growth. Additionally, the need for flexible, small-batch production and rapid turnaround times for complex trial designs is accelerating the adoption of advanced clinical trial manufacturing services.

The packaging, labeling, and blinding segment is expected to grow with a considerable CAGR during the forecast period. This is because packaging and labelling of newly discovered medicines help to protect drug integrity, ensuring patient safety, and maintaining strict regulatory compliance throughout a clinical trial. Some of the leading packaging companies are developing high-quality solutions for packing medicinal items before reaching the healthcare organizations.

Phase Insights

The Phase III Segment Dominated the Market in 2025

The phase III segment led the market in 2025 with a major share. This is because of its critical role in generating the clinical evidence required for regulatory approval and commercialization of new therapies. These large-scale trials assess treatment efficacy, monitor safety profiles, and evaluate optimal dosing across diverse patient populations, resulting in substantial demand for clinical trial supply and logistics services.

The phase II segment is expected to grow at the highest CAGR between 2026 and 2035. This is due to the increasing development of advanced therapies, including biologics, cell therapies, and gene therapies. Growing collaboration between pharmaceutical companies and contract development and manufacturing organizations (CDMOs) for Phase II studies is further driving demand for specialized clinical trial supply and logistics support.

Therapeutic Area Insights

The Cardiovascular Diseases Segment Dominated the Market in 2025

The cardiovascular diseases segment dominated the U.S. clinical trial supply and logistics market with the largest share in 2025. This is mainly due to the surging use of cell therapy for treating several types of cardiovascular diseases, such as coronary artery disease, cerebrovascular disease, and peripheral artery disease. In addition, the biotechnology companies are constantly conducting clinical trials to check the efficacy of vaccines.

The oncology segment is expected to expand at a notable CAGR during the forecast period. This is due to the rising cases of breast cancer among women, which increases the use of advanced medications. Also, the government is investing rapidly in accelerating cancer research to lower the prevalence of oncology disorders. The biopharma companies are collaborating with CDMO providers to conduct trials to validate the cancer vaccines.

End-User Insights

The Pharmaceuticals Segment Led the Market in 2025

The pharmaceuticals segment dominated the market in 2025. This is due to the surging adoption of 3PL services by the pharma brands for transporting medicinal items. Additionally, the rapid investment by the logistics companies to establish cold-storage facilities for storing precision medicines has boosted the segmental expansion.

The biologicals segment is expected to rise with the highest CAGR during the forecast period. This is owing to the rising use of advanced biologics, such as vaccines and gene therapies, for treating cancer. Biologics companies are investing significantly to integrate advanced technologies to enhance their product manufacturing and delivery processes.

Country-Level Analysis

• California: California is a major contributor due to its strong biotechnology ecosystem, high concentration of clinical research organizations (CROs), and presence of leading pharmaceutical and life sciences companies. The state's extensive clinical trial activity and advanced cold-chain logistics infrastructure support demand for trial supply management services.
• Massachusetts: Massachusetts plays a critical role through its dense network of biotech firms, academic medical centers, and research institutions, particularly in the Boston-Cambridge hub. Growing investment in precision medicine, cell therapy, and gene therapy trials is driving demand for specialized logistics and temperature-controlled distribution services.
• New Jersey: New Jersey is a key market due to the presence of numerous pharmaceutical company headquarters and established drug development operations. The state's proximity to major transportation networks and manufacturing facilities strengthens clinical trial supply chain efficiency.

Market Competitive Landscape: Leading Companies and Strategies

The U.S. clinical trial supply and logistics market is consolidated, with the leading companies holding more than 60% of the overall market share. The prominent players in this sector include Catalent, Thermo Fisher Scientific, Inc., Parexel International Corporation, and PRA Health Sciences. These brands are engaged in delivering high-quality logistics services and launching new solutions for operating clinical trials across the U.S.

In May 2026, Parexel launched ParexelAI. ParexelAI is a human-led AI service designed to accelerate the clinical development process in the U.S.

This industry has been suffering constantly due to the regulatory hurdles, along with the rising prices of fuel. The surging popularity of ultra-cold chain logistics and the growing adoption of direct-to-patient (DTP) delivery services by consumers will reshape the industry in the future.

U.S. Clinical Trial Supply and Logistics Market Companies

• Marken
• World Courier
• Fisher Clinical Services
• Catalent Clinical Supply Services
• Almac Group
• Parexel International Corporation
• Marken
• PCI Pharma Service
• PRA Healthsciences
• Myonex, Inc.

Recent Developments U.S. Clinical Trial Supply and Logistics Market (2025-2026)

• In May 2026, DHL launched a temperature-controlled air freight route. This new service will help in delivering pharma products across Europe and the U.S.(Source: https://www.stattimes.com)
• In April 2026, Paradigm Health launched the SPIRE. SPIRE is a scalable platform designed to enhance late-phase clinical evidence generation.(Source: https://www.prnewswire.com)
• In April 2026, the Food and Drug Administration (FDA) of the U.S. launched a new real-time clinical trials (RTCT) program. This new program was designed to approve and analyze the efficacy of medicines in the U.S. region.(Source: https://www.clinicaltrialsarena.com)

Segments Covered in the Report

By Service

• Logistics & Distribution
• Storage & Retention
• Packaging, Labeling, and Blinding
• Manufacturing
• Comparator Sourcing
• Others

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Therapeutic Area

• Oncology
• Cardiovascular Diseases
• Respiratory Diseases
• CNS and Mental Disorders
• Others

By End-User

• Pharmaceuticals
• Biologicals
• Medical Device